3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
74
Phase 3
43
Phase 1
43
Phase 1/2
39
Phase NA
5
Phase 4
2
Phase EARLY_PHASE1
1
Phase 2/3
1
Status
Withdrawn
1
Completed
1
Sponsor Class
OTHER
1
INDUSTRY
1
Study Type
Interventional
2
Sponsor
Cancer Type
Plasma cell
2
Conditions
Multiple Myeloma
2
Interventions
Dexamethasone
11
Lenalidomide
10
Bortezomib
10
Zoledronic Acid
8
ixazomib
4
daratumumab
4
Thalidomide
4
Melphalan
4
Cyclophosphamide
4
tocilizumab
3
Prednisone
3
pomalidomide
2
carfilzomib
2
Kyphoplasty
2
Filgrastim
2
Doxorubicin
2
Calcium Dobesilate
2
zanubrutinib
1
talquetamab
1
pegylated granulocyte colony-stimulating factor
1
montelukast
1
isatuximab
1
ibrutinib
1
fludarabine phosphate
1
fludarabine
1
exifone
1
dexamethasone acetate
1
dexamethasone 21-phosphate
1
auricularum
1
apixaban
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
2 trials
Recent
Start date
Enrollment
Phase 4
×
pomalidomide
×
Plasma cell
×
Clear all
NCT05555329
2025-04-22
POMAlternative
Amsterdam UMC, location VUmc
Phase 4
Completed
12 enrolled
NCT05183139
2022-05-03
US MM-7
Takeda
Phase 4
Withdrawn